Skip to content

5 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Oct 2026

Results from a multisite quality improvement initiative in solid tumor precision medicine.

582 Background: Timely, comprehensive biomarker testing is essential to identify actionable genomic alterations and guide targeted therapy in patients with advanced solid tumors. However, community and academic cancer centers often encounter delays in ordering, prolonged turnaround from diagnosis to results, an...

Amany R. Keruakous, W. Waugh, Samuel K. Caughron et al. · 0 citations
Open access Nov 2026

A Phase 1 Trial of Low-dose Gemcitabine Combined with ATR Inhibitor Elimusertib for Advanced Solid Tumors.

PURPOSE Preclinical data suggest that the anti-cancer efficacy of ATR inhibitors can be synergistically enhanced by low-dose gemcitabine. To test the clinical feasibility of this regimen, we conducted a phase 1 trial of low-dose gemcitabine combined with the ATR inhibitor elimusertib (BAY1895344). PATIENTS AND METHOD...

T. Jayakrishnan, Rebecca L. Porter, Alice P. Chen et al. · 0 citations
Sep 2026

Abstract A127: Targeting replication stress in pancreatic cancer: results of a phase 1b trial of azenosertib and gemcitabine in second line pancreatic cancer after progression on FOLFIRINOX

The combination of azenosertib and gemcitabine was associated with substantial myelosuppression in patients with metastatic PDAC previously treated with FOLFIRINOX, limiting further clinical evaluation of this dosing strategy.

B. Huffman, Haeseong Park, N. Jackson et al. · 0 citations
Sep 2026

Abstract PR011: Digenic CRISPR screening identifies novel KRAS/FGFR combination therapies for pancreatic cancer

These findings establish RAS-pathway focused combinatorial CRISPR screening as a robust approach for identifying clinically actionable combination vulnerabilities and nominate FGFR signaling as a lineage-specific mediator of KRAS inhibitor resistance in PDAC.

R. Ebright, Yao He, Alan Zhang et al. · 0 citations
Open access Sep 2026

Context-specific genetic interaction mapping reveals combinatorial KRAS/FGFR dependence in pancreatic cancer

Oncogenic KRAS drives >90% of pancreatic ductal adenocarcinoma (PDAC), and the pan-RAS inhibitor daraxonrasib doubles overall survival, but adaptive and acquired resistance limit the depth and duration of responses. To systematically map combination vulnerabilities, we developed RAS+, a digenic CRISPR knockout library...

R. Ebright, Yao He, Alan Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.